Welcome to Biomorph Technologies
We are a biotechnology company focusing primarily on the development of advanced diagnostics for hard-to-detect diseases. We are applying next-generation, multi-modal, multi-dimensional profiling of the patient's molecular and phenotypic response combined with advanced machine learning (ML) and artificial intelligence (AI) methods to identify and validate robust biomarkers for diagnostic, prognostic and disease progression/treatment monitoring
|
Lyme Disease |
A novel approach to an old problem |
Lyme Disease affects ~500,000 people every year in the US alone with increasing incidence rates, yet current diagnostic tools show only very limited capability in detecting the disease in its early stage when treatment is most effective. If misdiagnosed and/or left untreated, LD can cause debilitating long-term effects ranging from severe fatigue, skeletomuscular and joint paint, cognitive impairment ("brain fog") to heart problems. In addition to patient's suffering, LD represents a marked financial burden on the public health care system.
LD diagnosis: addressing an unmet urgent needCurrent approved molecular diagnostic method based on serologic testing of patient's sera provides a sensitivity of only 29% based on orthogonal, direct detection of the Borrelia spirochete via PCR. Furthermore, testing result may vary significantly not only due to lab-to-lab variation but also owing to geographical alterations in Borrelia strains.
|
Borrelia burgdorferi, the bacterium causing most LD cases in humans in the US, has been shown to possess a number of mechanisms to evade immunorecognition by the immune system. Furthermore, each person's immune system responds to pathogen exposure in slightly different, individualized ways, making the accurate diagnosis of LD especially complicated. Utilizing a novel approach that combines ML/AI with profiling of the immune system response in its broadest sense at the individual patient level enables discovery of robust biomarkers for diagnosis of early LD.
Customized approachUsing the most advanced approaches and methods available, we are able to gain deep insight into a body's response to a pathogen at the single-patient level. This provides the most detailed information about underlying diseases enabling patient-level data to be harnessed in the most efficient way.
|
Our partners, collaborators, and current funding sources
We enjoy our multi-faceted and multidisciplinary working environment enabled by our collaborations in the public, private, and industrial sectors of health care and biomedical research communities.
|
Our efforts in developing next-generation diagnostic for acute Lyme Disease have been generously funded by the National Institutes of Health/National Institute of Allergies and Infectious Diseases (NIH/NIAID) SBIR program
|